复星医药启动SRT-007临床试验 3219万元研发投入瞄准13.92亿美元市场

财中社
Dec 30, 2025

  12月30日,复星医药(600196/02196)发布公告,控股子公司成都星睿菁烜生物科技有限公司已于近期在中国境内启动了诊疗一体化核药项目SRT-007的Ⅰ期临床试验,适应症为PSMA阳性的转移性去势抵抗性前列腺癌的诊断和治疗。

  该项目包括镓[68Ga]PSMA-0057(诊断)和镥[177Lu]PSMA-0057(治疗)两个注射液。截至2025年11月,集团针对SRT-007的累计研发投入约为3219万元(未经审计;包含许可费)。

  全球范围内已获批上市的同靶点放射性药物为NOVARTIS AG的Pluvicto,2024年其全球销售额为13.92亿美元。

  2025年前三季度,复星医药实现收入293.93亿元,归母净利润25.23亿元。

(文章来源:财中社)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10